The gene-editing pioneer announced an important milestone.
The company provided an update on one of its lead drug candidates.
Missing Wall Street's revenue expectations was only one factor that led to a 26% drop.
The genetic-testing leader is growing at a triple-digit clip, but losses continue to mount.
The innovative biopharma announced third-quarter 2017 results Tuesday, but there weren't any surprises.
The second-largest storage and shipping container company is up 157% in the last year alone.
Boring stocks can be an investor's best friend. This water heater manufacturer proves it.
This seems to be a case of "sometimes stocks go up, sometimes they go down."
The company's growth is showing few signs of stopping, but losses continue to grow.
Third-quarter 2017 results show the company's high-growth business model is not without risks.
The diversified mining stock is about to welcome an entirely new revenue stream.
The Brazilian chemical manufacturer has since denied it, but not before it affected the share prices of at least three companies.
It's the same reason investors may want to think twice before buying any gold stock.
The stock slid after the company announced third-quarter 2017 earnings. Was the move warranted?
The biopharma reported third-quarter 2017 results and additional business updates.
The specialty chemical company released third-quarter 2017 results.
It makes sense on paper, but is little more than wishful thinking in reality.
The company reported positive results for its most important product (kind of).
The gene-editing company announced a big stock offering.
Beginning to see the benefit of past efforts, the company crushed Wall Street expectations.